← All indications
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Subtype terms (8)
More specific conditions that are subtypes of Head and Neck Neoplasms in the MeSH hierarchy.
- Esophageal Neoplasms
750 drugs (232 approved, 518 experimental)
- Facial Neoplasms
1 drug experimental
- Mouth Neoplasms
102 drugs (60 approved, 42 experimental)
- Otorhinolaryngologic Neoplasms
4 drugs (2 approved, 2 experimental)
- Parathyroid Neoplasms
17 drugs (13 approved, 4 experimental)
- Squamous Cell Carcinoma of Head and Neck
775 drugs (219 approved, 556 experimental)
- Thyroid Neoplasms
270 drugs (155 approved, 115 experimental)
- Tracheal Neoplasms
3 drugs approved
Drugs by status
Approved for this indication (4)
Phase 4 trials (39)
- mitomycin
- epinephrine
- bleomycin
- onabotulinumtoxinA
- nimotuzumab
- fluorouracil
- mirtazapine
- methadone
- dronabinol
- gabapentin
- apixaban
- cisplatin
- dobutamine
- venlafaxine
- thyme
- tc99m-tilmanocept
- dexmedetomidine
- bupropion
- dexamethasone
- capecitabine
- benzydamine
- phosphate
- ropivacaine
- fentanyl
- ketorolac
- albumin nanocolloid
- dopamine
- enoxaparin
- dopexamine
- monofluorophosphate
- +9 more
Phase 3 trials (80)
- pralsetinib
- doxepin
- uracil
- leucovorin
- cetirizine
- vincristine
- iseganan
- ipilimumab
- epoetin
- palifermin
- enoblituzumab
- hyaluronic acid
- epacadostat
- velimogene aliplasmid
- isotretinoin
- thyrotropin
- Synsepalum dulcificum
- vitamin e
- procaine benzylpenicillin
- pembrolizumab
- paclitaxel
- capsaicin
- porfiromycin
- tirapazamine
- oratest
- panitumumab
- clavulanate
- gemcitabine
- diphenhydramine
- fluconazole
- +50 more
Phase 2 trials (274)
- cixutumumab
- eos884448
- sd-101
- chlorhexidine
- methylene blue
- carmustine
- sitagliptin
- hydroxyurea
- folic acid
- polyphenols
- linsitinib
- hx4
- regn3767
- interleukin-12
- ketoprofen
- perindopril
- nrc-2694-a
- rc48-adc
- lurtotecan
- metronidazole
- bone autograft
- eribulin
- u3-1402
- varlilumab
- com701
- abt-510
- eniluracil
- alectinib
- aprepitant
- alm-488
- +244 more
Phase 1 trials (191)
- s-488211
- ac-aky-1189
- rtx-321
- recombinant oncolytic herpes simplex virus type 1 (r130)
- silicon phthalocyanine
- apx005m
- bi 754091
- rucaparib
- motexafin gadolinium
- aby-029
- brodalumab
- autologous natural killer cells
- iodixanol
- abbv-368
- lenvatinib
- abbv-400
- ethiodized oil
- synthetic human papillomavirus 16 e6 peptide
- 64cu-dota-ecl1i
- methylprednisolone
- dornase alfa
- allogeneic natural killer cells
- abbv-181
- vcn-01
- osimertinib
- vrp-encapsulated sarna encoding il-12
- picoplatin
- prt1419
- dk210
- alfatide
- +161 more
Other trials (40)
- ganoderma lucidum spore
- zenocutuzumab
- maltodextrin
- bvd-523
- technetium tc-99m sulfur colloid kit
- 99mtc ecdg
- ribavirin
- vorinostat
- [68ga]ga-nota-t4
- sugammadex
- Nimorazole
- diclofenac
- metformin
- bupivacaine
- olanzapine
- proflavine
- prilocaine
- panthenol
- neostigmine
- rubidium chloride rb-82
- 111in-j591
- glycopyrronium
- ap5346
- clinacanthus nutans
- boesenbergia rotunda
- varenicline
- citric acid
- methylphenidate
- ga-nota-rt4
- benzethonium
- +10 more
Organizations
Organization Involved with Phase 4 Indications (27)
- Region Skane
- University of Copenhagen
- Maastricht University
- University of Barcelona
- University of Toronto
- University of Nebraska
- Mt. Sinai Medical Center, Miami
- Bangladesh Medical University
- MedImmune
- University of Roma La Sapienza
- Shanxi Zhendong pharmaceutical Co. LTD.
- Medical University Innsbruck
- University of Campinas
- AstraZeneca
- Augusta University
- Lund University
- iOMEDICO AG
- National Institute of Mental Health (NIMH)
- Sun Pharmaceuticals
- University of New South Wales
- People's Liberation Army of China
- University of Tampere
- Sun Yat-Sen University
- University of Lorraine
- Aix-University of Marseille
- University of Heidelberg
- Sanofi
Organization Involved with Phase 3 Indications (138)
- Merck
- Free University of Amsterdam
- University of Bern
- Centre Jean Bernard
- Galera Therapeutics
- Isfahan University
- Guangzhou Double Bioproducts Co., Ltd
- Anglia Ruskin University
- University of Rochester
- University of Turin
- Royal Marsden Hospital NHS Trust
- Biotec Pharmacon ASA
- Harvard University
- National Cancer Institute, France
- Netherlands Cancer Institute
- Eli Lilly
- University of Hamburg
- University of California, Davis
- University of Texas at Houston
- University of Michigan
- Merck KGaA
- L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
- General Hospital Groeninge
- Taichung Veterans General Hospital
- Johns Hopkins University
- University of Brescia
- Cancer Research UK
- Yokohama City University
- Groupe Oncologie Radiotherapie Tete et Cou
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- +108 more
Organization Involved with Phase 2 Indications (254)
- State University of New York, Syracuse
- Holy Name Medical Center, Teaneck, NJ
- Dynavax Technologies Corporation
- University of Texas, San Antonio
- Central South University
- University of Florence
- Catalysis SL
- AIO-Studien-gGmbH
- Gruppo Oncologico del Nord-Ovest
- Instituto do Cancer do Estado de São Paulo
- Nang Kuang Pharmaceutical Co., Ltd.
- Biovitrum AB
- Jiangsu Cancer Institute & Hospital
- Professional Compounding Centers of America
- Kuwait Cancer Control Center
- TyrNovo Ltd.
- University of Wisconsin
- Shanghai Xuhui District Central Hospital
- Pfizer
- University of California, San Diego
- Kadoorie Foundation
- Centre Hospitalier de Saint-Brieuc
- Aventis
- Institut Sainte Catherine
- Chengdu Shi Endor Biological Engineering Technology Co., Ltd
- Government of Canada
- Providence Health & Services
- Assistance Publique - Hôpitaux de Paris
- University of Oklahoma
- University of Salamanca
- +224 more
Organization Involved with Phase 1 Indications (74)
- Leadiant Biosciences, Inc.
- Polyphenon Pharma
- West Virginia University
- Synermore Biologics Co., Ltd.
- NanoCarrier Co., Ltd.
- Verastem, Inc.
- American Society of Clinical Oncology
- Baromedical Research Foundation
- MacroGenics
- Allegheny Health Network
- Takeda
- Seattle Genetics
- Viralytics
- Instituto Nacional de Cancer, Brazil
- University of Basel
- Monash University
- ActoGeniX
- Eastern Virginia Medical School
- Erimos Pharmaceuticals
- Johnson and Johnson
- Celldex Therapeutics
- Isotrace Technologies
- Cellectar, Inc
- University of Birmingham
- Ichor Medical Systems Incorporated
- University of Virginia
- Summa Health System
- BioClever 2005 S.L.
- Cancer Immunotherapy Trials Network
- Wuxi No. 4 People's Hospital
- +44 more
Organization Involved with Other Experimental Indications (19)
- The Dale & Frances Hughes Cancer Center
- Aarhus University
- Karsh Family Research Fund
- Chang Bing Show Chwan Memorial Hospital
- University of Bordeaux
- Tel Aviv University
- TAP Pharmaceuticals
- Kentucky Lung Cancer Research Program
- Helsinn
- American College of Radiology
- Institut de Cancérologie de Lorraine
- University of Toulouse
- Hospital San Juan de Dios, Santiago
- Chulabhorn Hospital
- Kaohsiung Medical University
- Excel Diagnostic Imaging Clinics
- Naestved Hospital
- Latis Srl
- Hoag Memorial Hospital Presbyterian